Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Nov 5, 2024
Product Development
Are PD-1 agonists finally on the verge of impacting inflammation?
Eli Lilly is out of the race, but other companies believe they have differentiated products
BioCentury | Jun 19, 2024
Product Development
Clinical Report: Zentalis hold resurfaces WEE1 safety concerns
Plus data from BioNTech, MediLink, Nurix, Aerovate and more
BioCentury | Oct 20, 2022
Regulation
Inhibrx blazing regulatory trail in alpha-antitrypsin deficiency
San Diego company aims to be first to use functional AAT as a surrogate endpoint for AATD
BioCentury | Jul 2, 2021
Distillery Therapeutics
A single-shot, measles-vectored vaccine for Lassa virus
DISEASE CATEGORY: Infectious disease
INDICATION: Viral hemorrhagic fever Vaccination with a measles virus vector expressing Lassa virus glycoprotein and nucleoprotein could prevent Lassa virus
INDICATION: Viral hemorrhagic fever Vaccination with a measles virus vector expressing Lassa virus glycoprotein and nucleoprotein could prevent Lassa virus
BioCentury | Aug 11, 2020
Product Development
Remdesivir heads for FDA review as Gilead continues to build manufacturing pipeline
Plus data from Omeros, PTC and a call to make mAbs accessible
BioCentury | Jun 30, 2020
Product Development
Low-stakes 2018 deal with Regeneron leads to bump for Kiniksa on pericarditis readout
BioCentury | Jun 11, 2020
Product Development
J&J picks up pace for Warp Speed COVID-19 vaccine
Corning to produce glass packaging for countermeasures; plus progress on host-targeted therapies
BioCentury | May 15, 2020
Translation in Brief
Passage’s mouse, dog data for Krabbe disease; plus a predictive model of COVID-19 mortality, Sorrento’s COVID-19 antibody candidate and more
BioCentury’s roundup of preclinical news
BioCentury | Apr 28, 2020
Product Development
Actemra anti-IL-6 data in COVID-19 outshines Regeneron’s Kevzara readout
BioCentury is providing this story for free given the urgent need for information about the COVID-19 crisis. For more analysis, sign up for our daily email.
BioCentury | Dec 9, 2019
Company News
Novartis downsizing internal efforts on CAR T in solid tumors
How Novartis is shifting gears with its CAR T development plans
Items per page:
1 - 10 of 435